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Abstract
Introduction and hypothesis To investigate the associations
between single nucleotide polymorphism (SNP) type 1G/2G
at position −1607/−1608 of the matrix metalloproteinase
(MMP)-1 gene and SNP type 5A/6A at position −1612/-
1617 of the MMP-3 gene and the development of pelvic
organ prolapse (POP) in women.
Methods 133 patients with symptomatic POP were included
in the study group. The control group consisted of 132
women with a normal pelvic floor. 1G/2G MMP-1 and
5A/6A MMP-3 SNPs were determined by polymerase chain
reaction (PCR) and restriction fragments length polymor-
phism analysis.
Results When estimated individually none of the investigat-
ed SNPs were associated with POP. The combined MMP-1/
MMP-3 SNP analysis showed that the following poly-
morphic pairs were overrepresented in women with POP:
1G/2G −5A/6A, 2G/2G −5A/6A, 2G/2G −5A/5A, 1G/1G
−6A/6A, p00.005.
Conclusions The combined effect of −1607/−1608 MMP-1
and −1612/−1617 MMP-3 SNPs may contribute to the de-
velopment of POP in some women.
Keywords Pelvic organ prolapse . Polymorphism .
MMP-1 .MMP-3
Introduction
Pelvic organ prolapse (POP) affects 10–40% of older wom-
en [1]. Approximately 2% of women suffer from severe
disturbances of the pelvic floor and finally become candi-
dates for surgical repair [2]. The exact causes of POP are not
known, but this condition could be linked to disturbances in
connective tissue metabolism. The main structural protein of
connective tissue is type I collagen—a heterotrimer com-
prising two α-1(I) and single α-2(I) chains encoded by the
genes COL1A1 and COL1A2 respectively [3]. The impor-
tant physiological role of this protein is to provide support
for the pelvic floor structures. Metalloproteinases (MMPs)
are enzymes capable of degrading collagens and other ex-
tracellular matrix (ECM) components.MMP-1 plays a major
role in the collagen type I degradation, whereas MMP-3 is
able to activate other MMPs, including MMP-1 [4]
There is also evidence suggesting that POP might be
hereditary. A study by Jack et al. [5] showed that the risk
of POP is 5-fold higher in siblings of women with advanced
disease. Analysis of monozygotic and dizygotic twins indi-
cates that both genetic and environmental risk factors con-
tribute to the etiology of POP and stress urinary
incontinence (SUI) [6]. Dietz et al. [7], in a study of nullip-
arous young women, demonstrated the heritability of blad-
der neck mobility. Molecular mechanisms behind the
aforementioned findings remain unknown, but may involve
single nucleotide polymorphisms (SNPs) in the regulatory
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areas of the genes encoding proteins relevant to connective
tissue function. These polymorphisms change patterns of
collagens and MMPs genes expression. Some of the SNPs
in genes encoding ECM proteins are associated with bone
brittleness [8], heart conditions [9] or cancer susceptibility
[10]. The development of SUI, which shares many risk
factors with POP, is also associated with SNP in the gene
encoding α-1 chain of type I collagen [11].
Genes encoding collagen-degrading enzymes—matrix
metalloproteinase type 1 (collagenase-1) and matrix metal-
loproteinase type 3 (stromelysin)—are located on the long
arm of chromosome 11 [12]. SNP due to the insertion of the
extra guanine (G) base at position −1607/−1608 upstream
from the start of transcription creates a binding site for Ets
family transcription factors. The binding of Ets to the DNA
strand upregulates MMP-1 transcription and possibly
increases the tissue activity of this enzyme.
The main substrates for MMP-3 are collagens type II, III,
and IV [13]. However, the substrate specificity of MMP-3
encompasses several other collagens, fibronectin, gelatin,
and elastin [14]. Another important feature of the MMP-3
is the ability to activate other members of the MMP family
[15]. The insertion of the adenosine (A) base in the promoter
of theMMP-3 gene, at position −1612/−1617 upstream from
the start of transcription, creates a polymonomeric run of six
adenosines (6A allele), while the other variant has five
adenosines (5A allele). The presence of the 6A allele ena-
bles binding of the repressor ZBP-89 that downregulates the
expression of the MMP-3 gene [16]. We hypothesized that
modifications of ECM metabolism caused by polymor-
phisms of the MMP genes could contribute to the develop-
ment of POP. Therefore, the aim of the study was to estimate
the associations between the SNP at position −1607/−1608
of theMMP-1 gene and the SNP at position −1612/−1617 of
the MMP-3 gene, and between the combinations of the
genotypes created by the above-mentioned SNPs and the
risk of pelvic organ prolapse.
Materials and methods
The study was approved by the Institutional Ethics Com-
mittee. All patients gave their informed consent. Recruit-
ment took place from 2007 to 2008. All patients were
referred from outpatient settings and were asked to partici-
pate in this study after admission. One hundred and thirty-
three women with symptomatic pelvic organ prolapse
(grades II, III, and IV; POPQ) were included into the study
group [17]. These patients were subjected to pelvic floor
repair procedures. Anterior and posterior vaginal wall
defects were treated by the insertion of anterior mesh im-
plant or posterior mesh implant, respectively. For combined
anterior/posterior defects anterior and posterior implants
were placed during a single surgical procedure. Besides
mesh surgery some patients required colpoperineoplasty
for the perineal body reinforcement.
The control group consisted of 132 women without sig-
nificant POP (grades 0, I; POPQ). The vast majority of these
patients were admitted with uterine myomas and subse-
quently underwent total abdominal hysterectomy or supra-
cervical abdominal hysterectomy. The rest of the control
group consisted of patients with dysfunctional uterine bleed-
ing (DUB). They were subjected to endometrial biopsy or in
a few cases to dilatation and curettage. All subjects in the
study and the control group were assessed with the same
diagnostic work-up that included measurement of the vital
signs, body weight and height for BMI calculation, physical
examination with assessment of POP, bimanual gynecolog-
ical examination, and routine pre-operative laboratory tests.
Patients with connective tissue and autoimmune diseases,
joint and bone diseases, cancer, chronic inflammation (e.g.,
Crohn’s disease, ulcerative colitis) or any serious or life-
threatening conditions were excluded from the study.
Laboratory procedures
Blood samples were taken prior to surgery into tubes con-
taining anticoagulant EDTA. Genomic DNA was extracted
from whole-blood leukocytes using a commercially avail-
able kit (GenomicPrep Blood DNA Isolation Kit, Amer-
sham Biosciences, USA). DNA was stored at −20°C until
used. Determination of MMP-1 and MMP-3 polymorphisms
was carried out using polymerase chain reaction (PCR) and
restriction fragments length polymorphism (RFLP) analysis.
MMP-1 polymorphism
Polymerase chain reaction was performed (Biometra T per-
sonal Thermocycler, Whatman Biometra, Germany) using
40 ng of DNA per reaction. For amplification, the Taq DNA
polymerase (Promega, Madison, WI, USA) and commer-
cially obtained oligonucleotide primers; 5′-TGACTTT-
TAAAACATAGTCTATGTTCA ′ (forward) and 5 ′-
TCTTGGATTGATTTGAGATAAGTCATAGC-3′ (reverse)
were used. The 40 amplification cycles were preceded by
denaturation at 99°C for 7 min. Annealing was carried out at
52°C for 30 s, elongation at 72°C for 45 s, and denaturation
94°C for 30 s. A final primer extension was carried out at
72°C for 5 min. Reverse primer was designed to introduce
restriction site for the enzyme AluI (AGCT) by replacing T
with a G at the second position close to 3′ end of the reverse
primer [18]. The final recognition of the MMP-1 polymor-
phism was based on analysis of RFLP. PCR products (10 μl)
were digested with AluI (Fermentas) (10 U, 37°C, 16 h),
separated on 3% agarose gel, and stained with ethidium
bromide (Fig. 1).
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MMP-3 polymorphism
Polymerase chain reaction was carried out using 40 ng
DNA per we l l . The PCR pr ime r s we re : 5 ′ -
GGTTCTCCATTCCTTTGATGGGGGGAAAgA-3 ′
(forward) and 5′-CTTCCTGGAATTTCACATCACTGC
CACCACT-3′ (reverse). The conditions of PCR reac-
tions were as follows: denaturation 5 min at 98°C
followed by 40 cycles of annealing 30 s 58°C, elonga-
tion 30 s 72°C and denaturation 30 s 94°C with final
elongation 5 min 72°C. PCR products (10 μl) were
digested with Tht111 10 U/sample at 37°C, 16 h and
separated on 3% agarose gel [19]. After staining with
ethidium bromide identification of the type of polymor-
phism was carried out (Fig. 2).
Statistical analysis
Power calculations were performed prior to the study, based
on the data from the HapMap project regarding the allele
frequency. We assumed that 130 patients in each group
would have been enough to show the association be-
tween the polymorphisms investigated and POP. Pear-
son’s Chi-squared test was used for the comparison of
the polymorphism frequencies between study and con-
trol patients. Because the distributions of age, parity,
body mass index, and menopausal status were skewed,
differences in means and medians were tested using the
Mann–Whitney test. The statistical significance for devi-
ations from the Hardy–Weinberg equilibrium were de-
termined using Pearson’s Chi-squared test. All statistics
were performed with Statistica v.6.1 (StatSoft, Tulsa,
OK, USA).
Results
The clinical characteristics of the patients are given in
Table 1. The patients in the control group were younger
than their counterparts in the study group. Not surpris-
ingly, fewer patients in the control group had entered
the menopause (Table 1).
MMP-1 alleles/genotypes analysis
The frequencies of the 1G/1G, 1G/2G, 2G/2G alleles were not
consistent with the Hardy–Weinberg equilibrium. Table 2 dis-
plays the frequencies of the 1G and 2 G alleles and theMMP-1
genotype distribution in the groups being investigated. We did
not find any statistically significant differences between the
study group and controls.
MMP-3 alleles/genotypes analysis
The frequencies of the 5A/5A, 5A/6A, and 6A/6A alleles
were not in Hardy–Weinberg equilibrium. Table 3 shows the
frequency of the 5A and 6A alleles and MMP-3 genotypes
distribution in study subjects and controls. The statistically
significant differences between the study and control groups
were not found. The exact determination of SNPs in 7 POP
samples was not possible because PCR-RFLPs repeatedly
gave ambiguous results. These patients were not included in
the analysis.
The combination of the MMP-1 and MMP-3 SNPs
Table 4 displays the combination of theMMP-1 andMMP-3
SNPs in the study and control groups. The comparison of
the frequencies of the combination of the two genotypes,
one for MMP-1 and the other for MMP-3, showed that some
of them were over-represented (1G/2G–5A/6A, 2G/2G–5A/
6A, 2G/2G–5A/5A, 1G/1G–6A/6A, p00.005) in women
with POP.
Fig. 2 Analysis of the MMP-3 5A/6A polymorphism. PCR products
were digested with Tht111 restriction endonuclease and separated on
3% agarose gel. The ethidium bromide-stained gel was visualized using
UV transillumination. A single band of 129 bp corresponds to the 6A/
6A homozygote, three bands of 129, 97 and 32 bp to the 5A/6A
heterozygote and two bands of 97 and 32 bp to the 5A/5A homozygote
(the smallest band [32 bp] is not visible)
Fig. 1 Analysis of MMP-1 1G/2G polymorphism. Polymerase chain
reaction (PCR) products were digested with AluI restriction endonu-
clease and separated on 3% agarose gel. The ethidium bromide-stained
gel was visualized using UV transillumination. A single band of
269 bp corresponds to 2G/2G homozygote, two bands of 241 and
28 bp to 1G/1G homozygote, and three bands of 269, 241, and 28 bp
to heterozygote 1G/2G (the smallest band [28 bp] is not visible)
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There is also evidence that some combinations of geno-
types appear with lesser frequency in women with POP
(1G/2G–5A/5A, 2G/2G–6A/6A).
Discussion
The rates of transcription of the MMP genes are influ-
enced by SNPs in their regulatory elements. Studies
show that the 2G/2G MMP-1 polymorphism is linked
to the aggressive phenotype and the process of metas-
tasis formation in cancers [20, 21]. The elevated tissue
MMP-1 activity in carriers of 2G/2G genotype could be
responsible for the degradation of fibrillar collagens and
other components of ECM, thus facilitating the progress
of the neoplastic disease. Other data suggest that the
polymorphism-related modifications of expression of the
MMP-1 gene are also involved in the pathogenesis of
idiopathic pulmonary fibrosis [22] and liver cirrhosis in
HCV-infected patients [23]. Both idiopathic pulmonary
fibrosis and liver cirrhosis were associated with the 2G/
2G MMP-1 variant, but unlike cancer the effect of this
polymorphism is increased collagen content in the
organs involved. Nonetheless, these results further sup-
port the role of the 1G/2G MMP-1 SNP in the regula-
tion of tissue collagen content.
The SNP at position –1612/–1617 forms clinically
important variants of the MMP-3 gene. 5A/5A individ-
uals have the greatest transcription of the MMP-3 gene,
whereas those with 6A/6A SNP have the lowest level of
the transcription [16]. The increased MMP-3 activity in
colorectal cancer suggests that this enzyme might play a
role in the progression of the disease [24]. In contrast,
the reduced activity of MMP-3 in 6A/6A individuals
with coronary heart disease contributed to the increased
risk of restenosis, perhaps because of the failure of
connective tissue remodeling [25].
We speculated that similar mechanisms related to the
1G/2G MMP-1 and 5A/6A MMP-3 SNPs might exist
within the pelvic floor connective tissue in women with
clinically significant pelvic organ prolapse. Theoretical-
ly, subjects with 2G/2G MMP-1 polymorphism could
have elevated MMP-1 activity and the increased rate
of collagen type I degradation. Also, the higher connec-
tive tissue MMP-3 activity in 5A/5A subjects may be
responsible for accelerating the breakdown of collagen
and other ECM components. On clinical grounds, both
SNPs could result in the elevation of the risk of POP.
Our results did not support this view because, when
considered separately, either the 1G/2G MMP-1 or the
5A/6A MMP-3 SNP is not associated with POP devel-
opment. The other explanation of our results is that the
association is simply too small to detect. This is in
contrast to the results of the study by Vishwajit et al.
[26], where a link between the 2G/2G MMP-1 polymor-
phism and the risk of POP and SUI was found. The
explanation for this discrepancy could be the weak
statistical power of this study with just 28 subjects
enrolled. However, the results of the study by Ferrari
et al. showed that the MMP-1 polymorphism could be
linked to the susceptibility to POP [27]. Interestingly,
these associations did not exist for MMP-3 and MMP-9
polymorphisms.
The analysis of allelic pairs showed that on the one
hand, patients with 2G/2G MMP-1 and 5A/5A as well
as 5A/6A MMP-3 polymorphisms appear to be more
prone to developing POP. Genotypes with the greatest
transcription levels of the MMP-1 and MMP-3 genes
carry the greatest risk of POP. Therefore, it is possible
that to become clinically evident the biological effect of
the 2G/2G MMP-1 variant has to be enhanced by the
5A/5A or the 5A/6A MMP-3 SNP. On the other hand,
the combination of the 2G/2G MMP-1 polymorphism
and the 6A/6A MMP-3 polymorphism appears to be
associated with a normal pelvic floor. Thus, we can
speculate that the simultaneous presence of the 6A/6A
MMP-3 and the 2G/2G MMP-1 SNPs diminishes the






Age (years) 50.8 57.3 <0.05
BMI (kg/m2) 27 27.7 ns
Parity (median) 2 2 ns
Cesarean section (median) 1 1,5 ns
Menopause (n) 58 79 <0.05
Table 2 Frequency of the 1G and 2G alleles and MMP-1 genotype distribution in the groups being investigated
Group MMP-1 polymorphism (position −1607/−1608)
1G/1G Percentage 1G/2G Percentage 2G/2G Percentage Pearson’s Chi-squared test
Control (n0132) 45 34.1 54 40.9 33 25 χ200.07, p01
Study (n0133) 47 35.3 54 40.6 32 24.1
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rate of collagen type I degradation. Of course, the
mechanisms behind this phenomenon have remained
elusive, but a possible explanation of our findings may
lie in the regulation of the tissue activity of the MMPs.
In addition to cytokines and growth factors MMPs
themselves also modulate their activity. MMP-3 is able
to activate proMMP-1, further augmenting the tissue
activity of MMP-1 [15]. This may explain why women
carrying the 2G/2G–5A/5A and 2G/2G–5A/6A geno-
types are at greater risk of having clinically significant
POP. Also, the 6A/6A variant seemed to play a protec-
tive role in POP only in conjunction with the 2G/2G
MMP-1 genotype. This finding corresponds with data
showing a lower risk of lung and breast cancers in
carriers of this polymorphic variant [19, 28]. However,
the same polymorphic variant can also exert deleterious
effects. The lower tissue activity of MMP-3 in 6A/6A
patients alters the remodeling process of ECM in the
direction of facilitating the progress of atherosclerosis
[29].
It is likely that MMPs and other regulatory proteins
not estimated in this study are involved in the develop-
ment of POP. For example, in patients with recurrent
hernia there are increased connective tissue levels of
MMP-1 and MMP-13 mRNAs and the levels of the
corresponding proteins [30]. Tissue inhibitors of
metalloproteinases (TIMPs) are able to inhibit active
forms of MMPs. Thus, the connective tissue contents
of TIMPs are crucial for MMP activity in vivo. The
example came from a gastric cancer study in which the
diminished TIMP-2 expression related to the gene pro-
moter polymorphism contributed to rapid dissemination
and worse patient survival [31]. Since our study was
limited to the MMP-1 and MMP-3 polymorphisms, the
role of TIMPs in the development of pelvic floor
defects was not assessed. Therefore, we cannot rule
out that the interpretation of our results would be dif-
ferent if the determination of TIMPs polymorphisms had
been carried out. Undoubtedly, the weakness of our
study is that SNP distribution was not in Hardy–Wein-
berg equilibrium. This could be attributed to the non-
random selection of control and study subjects or too
small a number of participants. However, the latter issue
is less likely because the number of women recruited is
comparable to those of similar SNP studies. Also, the
control and study groups did not fully match with
regard to the demographic and the clinical character-
istics. This issue was a consequence of the fact that
after the exclusion of malignancies the vast majority of
the remaining patients were treated for DUB, symptom-
atic myomas or typical ailments of the late menopause,
e.g., POP, SUI. Another limitation is the weak statistical
power of the study caused by the unexpected distribu-
tion of allele frequencies in our patients. This finding
could be explained by the genetic differences within
Caucasian populations.
Besides clinical and environmental factors the distur-
bances in the female pelvic floor may also be depen-
dent on the polymorphisms of the genes encoding the
ECM components. The results of our study showed that
certain combinations of the 1G/2G MMP-1 and the 5A/
6A MMP-3 promoter SNPs are more likely to occur in
women with POP than in the population with a normal
pelvic floor. This newly found association should be
considered, along with prolonged hypoestrogenism,
multiple vaginal births, pelvic floor surgery, as a genet-
ic risk factor for the development of pelvic organ
prolapse.
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Table 3 The frequency of the 5A and 6A alleles and MMP-3 genotype distribution in study subjects and controls
Group MMP-3 polymorphism (position −1612/−1617)
5A/5A Percentage 5A/6A Percentage 6A/6A Percentage Pearson’s Chi-squared test
Control (n 0132) 34 25.8 79 59.9 19 14.4 χ200.6, p00.8
Study (n 0126) 28 22.2 81 64.3 17 13.5
Table 4 Genotype combinations of the position −1607/−1608 MMP-1
polymorphism and the position −1612/−1617 MMP-3 polymorphism
Control group, freq. of polymorphisms (%) MMP-3
5A/5A 5A/6A 6A/6A
MMP-1 1G/1G 39.5 58.1 2.3
1G/2G 26.4 56.6 17
2G/2G 6.2 68.7 25
Study group, freq. of polymorphisms (%)
MMP-1 1G/1G 39.5 51.2 9.3b
1G/2G 14a 68b 18
2G/2G 10.3b 75.9b 13.8a
The results are the observed frequencies of the study (POP) patients
and controls. Pearson’s Chi squared test028.6, p00.005,
a SNPs underrepresented in the study group
b SNPs overrepresented in the study group
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